Designing a Multi-epitope Peptide Vaccine Against COVID-19 Variants Utilizing In-silico Tools

Abstract

Background and Aim: SARS-CoV-2 is the causative agent of Coronavirus 2019 or COVID-19 in the world. Novel coronavirus disease is a respiratory disease. To date, there have been challenges in the treatment for COVID-19 and emerged new variants like UK B1.1.7. Accordingly, an effective prevention regime is needed for this infection, which covers most variants. The purpose of this research was to predict the conserved epitopes of Spike and Nucleocapsid proteins from SARS-CoV-2 for the design of a novel coronavirus 2019 multi-epitope vaccine using in silico tools.Materials and Methods: Computational analysis and immunoinformatics approaches include identification of potential conserve epitopes and selection of epitopes based on allergenicity, toxicity, antigenicity, and molecular docking were used for epitope prediction and screening. In the next step, selected segments of the epitopes were attached by the suitable linkers. Finally, Maltese-bound protein (MBP) as an adjuvant was added to the novel vaccine structure. The secondary and third structures of the designed multi-epitope vaccine were predicted via immunoinformatics algorithms. Predicted structure refined and validated for attaining best stability. In the end, immunoinformatics evaluation, molecular docking, and molecular dynamics were performed to confirm vaccine efficiency. Codon optimization and in silico cloning were done to ensure the expression yield of the novel multi-epitope vaccine in the target host.Results: This study showed that our data support the suggestion that the designed vaccine could induce immune responses against SARS-CoV-2 variants. Conclusion:The structure designed had acceptable quality with software reviews. Further in vitro and in vivo experiments are needed to confirm the safety and immunogenicity of the candidate vaccine.

Designing a Multiple-Epitope Vaccine Candidate against Leishmania major and Leishmania infantum for Monocyte-Derived Exosome Preparation

“…To construct an efficient multiple-epitope vaccine, a pool of epitopes were extracted from the highlighted sequences and epitopes with binding capacity to their respective HLA alleles were selected as joined via appropriate linkers. The linker sequences were selected based on the previous studies ( 11 ). Furthermore, the PAPAPA linker was used to connect adjuvant sequences to N and C terminals of the multiple-epitope peptide.…”

Immunoinformatics analysis of Brucella melitensis to approach a suitable vaccine against brucellosis

“…The results of Bcepred server are presented in graphic and tabular format. This server predicts epitopes with 58.7% accuracy and 2.38 threshold [ 36 ].…”

Plants against cancer: the immune-boosting herbal microbiome: not of the plant, but in the plant. Basic concepts, introduction, and future resource for vaccine adjuvant discovery

“…The factors that maintain the M2 phenotype are still debated, but reportedly involve continuous exposure to cytokines released from the stroma/tumor itself, such as suppressive E-receptor factor, hyaluronan ( 193 – 196 ) or the dominance of gram-negative bacteria in the ‘tumor microbiome,’ as seen in gemcitabine-resistant pancreatic ductal carcinoma ( 197 ). The future therapeutic use of LPS/TLR4 agonists could enhance the efficacy of immune checkpoint inhibitors (ICIs) ( 198 – 201 ), increase the effectiveness of monoclonal antibodies (MAbs) (e.g., trastuzumab) ( 202 ) and boost the potency of platinum- and taxol-based chemotherapies ( 203 ). As of now, TLR4 agonists are primarily used as adjuvants in tumor vaccines ( 204 – 207 ) and in adoptive anti-tumor immunotherapies ( 208 ) as well as in dendritic cell-based therapies specific to tumor antigens ( 209 ).…”